Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Akero Therapeutics Inc
(NQ:
AKRO
)
19.66
-0.05 (-0.25%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Akero Therapeutics Inc
< Previous
1
2
3
4
5
6
Next >
AKRO INVESTOR ALERT: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AKRO
May 04, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Exscientia, and Akero and Encourages Investors to Contact the Firm
May 03, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Akero Therapeutics, Inc. (AKRO) Investors
May 03, 2024
From
Kirby McInerney LLP
Via
GlobeNewswire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Akero Therapeutics, Inc. (AKRO) on Behalf of Investors
May 03, 2024
From
Glancy Prongay & Murray LLP
Via
Business Wire
Akero Therapeutics, Inc. (AKRO) Investor Notice: Robbins LLP Reminds Stockholders of the Akero Therapeutics, Inc. Class Action
May 02, 2024
From
Robbins LLP
Via
Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Akero Therapeutics, Inc. (AKRO) on Behalf of Investors
May 02, 2024
From
Law Offices of Howard G. Smith
Via
Business Wire
AKRO INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Akero Therapeutics, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Class Action Lawsuit
May 02, 2024
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Akero Therapeutics, Inc. (AKRO) on Behalf of Investors
May 02, 2024
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Akero Therapeutics (AKRO) Slides After Failed Trial, Hit With Class Action Lawsuit – Hagens Berman
May 02, 2024
From
Hagens Berman Sobol Shapiro LLP
Via
GlobeNewswire
AKRO INVESTOR NOTICE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AKRO
May 01, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
NASDAQ: AKRO: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Securities Class Action Lawsuit Filed Against Akero Therapeutics, Inc.
April 30, 2024
From
Kessler Topaz Meltzer & Check, LLP
Via
Business Wire
Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer
April 30, 2024
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Stockholder Alert: Robbins LLP Informs Investors of the Class Action Filed Against Akero Therapeutics, Inc. (AKRO)
April 30, 2024
From
Robbins LLP
Via
GlobeNewswire
AKERO ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Akero Therapeutics, Inc. and Encourages Investors to Contact the Firm
April 29, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AKRO
April 29, 2024
From
Rosen Law Firm
Via
Business Wire
AKRO INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Akero Therapeutics, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Class Action Lawsuit
April 29, 2024
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Akero Therapeutics, Inc.with Losses to Contact the Firm
April 28, 2024
From
Schall Law
Via
GlobeNewswire
AKERO THERAPEUTICS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. - AKRO
April 28, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
AKRO Investor Notice: Abraham, Fruchter & Twersky, LLP Investigating Claims on Behalf of Investors of Akero Therapeutics (NASDAQ:AKRO)
March 20, 2024
From
Abraham, Fruchter & Twersky, LLP
Via
GlobeNewswire
Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
March 08, 2024
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology
March 07, 2024
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Akero Therapeutics Announces Pricing of Public Offering of Common Stock
March 05, 2024
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Akero Therapeutics Announces Proposed Public Offering of Common Stock
March 04, 2024
From
Akero Therapeutics Inc.
Via
GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
March 04, 2024
Via
Benzinga
Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
March 04, 2024
Shares of Bitdeer Technologies Group (NASDAQ: BTDR) rose sharply during Monday’s session after the company reported preliminary fourth-quarter financial results, announced the successful testing of its...
Via
Benzinga
Akero Therapeutics' Stock Is Soaring Monday - Here's Why
March 04, 2024
Akero Therapeutics success in HARMONY Phase 2b study for efruxifermin. EFX demonstrated sustained efficacy and well-tolerance, marking a major milestone in liver disease treatment.
Via
Benzinga
Akero Rockets 27%, Prodding Rival 89bio Higher, On Promising Liver Disease Treatment
March 04, 2024
Akero and 89bio stocks are poised to top their 200-day moving averages on the results of Akero's MASH treatment in midstage testing.
Via
Investor's Business Daily
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
March 04, 2024
We're starting off the trading week with a breakdown of all the biggest pre-market stock movers worth watching on Monday morning!
Via
InvestorPlace
Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
March 04, 2024
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Super Micro Computer, Deckers Outdoor And Other Big Stocks Moving Higher In Monday's Pre-Market Session
March 04, 2024
U.S. stock futures were mixed this morning, with the Dow futures trading lower by around 50 points on Monday. Shares of Super Micro Computer, Inc. (NASDAQ: SMCI) rose sharply in today’s pre-market...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.